Loading…
NGL Fine-Chem (NGLFINE)₹2,935+1.97%Pharmaceuticals
NGL Fine-Chem is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a P/E of 31.7 against a peer median of 31.3, and ROCE of 19.0% against a peer median of 19.0%, and latest-quarter sales growth of 33.8% against a peer median of 18.2%. By market cap it is #10 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fredun Pharmaceuticals | 2,245 | 49.1 | 21.0 | 15.6 | 0.81 | 0.0 | 636 | 33 | 90.0 | 85.8 | vs NGLFINE |
| Sai Parenterals | 2,237 | 156.2 | 5.0 | 4.9 | 0.96 | 0.0 | 382 | 14 | 435.6 | 455.2 | vs NGLFINE |
| Panacea Biotec | 2,206 | — | −2.0 | −2.4 | 0.03 | 0.0 | 641 | −7 | 19.5 | −44.3 | vs NGLFINE |
| Beta Drugs | 2,089 | 39.0 | 19.0 | 18.9 | 0.11 | 0.0 | 384 | 41 | 33.0 | 58.3 | vs NGLFINE |
| Indoco Remedies | 2,025 | 63.4 | 1.0 | −9.4 | 1.17 | 0.1 | 1,848 | −99 | 7.2 | — | vs NGLFINE |
| Windlas Biotech | 2,007 | 30.8 | 16.0 | 12.2 | 0.06 | 0.6 | 906 | 66 | 18.2 | 0.0 | vs NGLFINE |
| Hester Biosciences | 1,963 | 14.4 | 15.0 | 15.9 | 0.54 | 0.5 | 332 | 57 | −8.5 | 471.0 | vs NGLFINE |
| Venus Remedies | 1,941 | 15.9 | 21.0 | 15.7 | 0.02 | 0.7 | 769 | 103 | 13.3 | 30.0 | vs NGLFINE |
| Syncom Formulations (India) | 1,885 | 21.6 | 27.1 | 20.2 | 0.00 | 0.5 | 488 | 76 | 7.7 | 56.3 | vs NGLFINE |
| NGL Fine-Chem | 1,814 | 31.7 | 19.0 | 17.4 | 0.37 | 0.1 | 500 | 48 | 33.8 | 100.0 | — |
| Amrutanjan Health Care | 1,502 | 26.0 | 25.0 | 18.5 | 0.00 | 1.1 | 503 | 58 | 11.0 | 6.6 | vs NGLFINE |
| Peer median | 2,007 | 31.3 | 19.0 | 15.7 | 0.11 | 0.1 | 503 | 48 | 18.2 | 57.3 |
Listed companies closest to NGL Fine-Chem in Pharmaceuticals include Fredun Pharmaceuticals, Sai Parenterals, Panacea Biotec, Beta Drugs, Indoco Remedies, Windlas Biotech, Hester Biosciences, Venus Remedies.
Fredun Pharmaceuticals, with a market cap of ₹2,245 Cr.
NGL Fine-Chem trades at a P/E of 31.7; the median of its peer set is 31.3. A P/E above or below the median is a description, not a judgement on value.
NGL Fine-Chem's return on capital employed is 19.0%, above the peer median of 19.0%.